Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006. In April 2005, the FDA and patient advocacy groups requested an expanded access programme to both provide lenali...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Christine, Reece, Donna E, Siegel, David, Niesvizky, Ruben, Boccia, Ralph V, Stadtmauer, Edward A, Abonour, Rafat, Richardson, Paul, Matous, Jeffrey, Kumar, Shaji, Bahlis, Nizar J, Alsina, Melissa, Vescio, Robert, Coutre, Steven E, Pietronigro, Dennis, Knight, Robert D, Zeldis, Jerome B, Rajkumar, Vincent
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2009
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728892/
https://www.ncbi.nlm.nih.gov/pubmed/19545290
http://dx.doi.org/10.1111/j.1365-2141.2009.07728.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728892/
https://www.ncbi.nlm.nih.gov/pubmed/19545290
http://dx.doi.org/10.1111/j.1365-2141.2009.07728.x

Ejemplares similares